Sep 15, 2025, 08:42
W. Alberto Sifuentes Giraldo Highlights 4-Fold Higher Preeclampsia Risk in Pregnant SLE Patients with LN and APS
W. Alberto Sifuentes Giraldo, Rheumatologist at Hospital Nuestra Señora de Sonsoles (Sacyl), has shared a post on LinkedIn:
“Pregnant women with systemic lupus erythematosus (SLE) face a substantially higher risk of preeclampsia (PE) and PE with severity criteria, with both lupus nephritis (LN) and antiphospholipid syndrome (APS) emerging as strong, independent risk factors for these complications, as confirmed by a Spanish nation-wide cohort study:
- LN and APS nearly double PE risk beyond SLE by itself. Both conditions potentiate each other, since the combination of LN and APS results in a 4-fold higher risk of PE compared with SLE women without any of them.
- Renal involvement in SLE confers a high likelihood of developing PE, particularly in the more severe forms; LN independently triples PE with severity criteria odds.
These findings indicate that LN, and APS should be a fundamental factor in pre-conceptional planning, PE risk stratification, pregnancy monitoring, and prognostic assessment of PE in SLE patients.”

More insights on Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn Ruksakulpiwat։ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin